Late-Life GLP-1 Treatment Increases Lifespan in Female Mice
Key claim: Semaglutide given late in life increased median lifespan in female mice by more than 12% and improved various health markers.
Abstract
In a new study, semaglutide given late in life increased median lifespan in female mice by more than 12% and improved various health markers. Semaglutide’s …
Why this matters
Until now the GLP-1-as-geroprotector case rested on cardiovascular/renal outcome RCTs in humans plus mechanistic speculation — no direct lifespan data. A >12% median lifespan extension in female mice, delivered late in life, is the first preclinical readout that speaks to aging itself rather than metabolic disease, and it will be seized on by longevity clinics already prescribing semaglutide off-label. The finding is single-sex, single-species, and reported via news channel rather than peer-reviewed publication, so the divergence between the trend momentum it will generate and its actual evidentiary weight is the story to watch.